Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on X:
“The results of POTOMAC trial are out in The Lancet simultaneously released with ESMO25 presentation.
Happy to share our thoughts on this also out in the accompanying editorial.
Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer – The Lancet.”
Title: Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer
Authors: Andrea Necchi, Alberto Briganti, Francesco Montorsi
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO Announces the 2025 Society Award Winners
POTOMAC Trial at ESMO 2025: Durvalumab Plus BCG Improves Outcomes in High-Risk NMIBC
